S2 Ep37: Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

PER Podcast Sessions

Content provided by PER Spectives and PER® Spectives. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by PER Spectives and PER® Spectives or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

21d ago 32:37

MP3•Episode home

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Eileen O’Reilly, MD, and Brian Wolpin, MD, MPH, discuss current principles for molecular testing and emerging targeted therapy approaches for patients with metastatic pancreatic ductal adenocarcinoma.
Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

Assess the role of molecular profiling to identify actionable alterations in patients with advanced pancreatic adenocarcinoma (PDAC)
Analyze clinical data from key trials evaluating emerging therapeutic agents for metastatic PDAC

Acknowledgment of Educational Grant Support
This activity is supported by an educational grant from Revolution Medicines.

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions on How to Receive Credit

1. Listen to this podcast in its entirety.
2. Go to gotoper.com/credit and enter code: 9235
3. Answer the evaluation questions.
4. Request credit using the drop-down menu.

You may immediately download your certificate.

Chair:

Eileen M. O’Reilly, MD
Professor of Medicine
Winthrop Rockefeller Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary & Neuroendocrine Cancers, Gastrointestinal Oncology Service
Associate Director, David M. Rubenstein Center for Pancreatic Cancer Research
Memorial Sloan Kettering Cancer Center
New York, NY
Disclosures: Consultant: AbbVie, Alligator Bioscience, AstraZeneca, Autem, Berry Genomics, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Eisai, Exelixis, Genentech/Roche, Incyte, Ipsen, J-Pharma, Merck, Merus, Neogene, Novartis, Servier, Tango, Tempus, Vector, Yiviva; Institutional research support: Agenus, Arcus, AstraZeneca, BioNTech, Bristol Myers Squibb, Elicio, Genentech/Roche, Helsinn, Parker Institute, Pertzye, Puma, QED, Servier, Yiviva.
Faculty:

Brian Wolpin, MD, MPH
Professor of Medicine
Director, Gastrointestinal Cancer Center
Director, Hale Family Center for Pancreatic Cancer Research
Robert T. & Judith B. Hale Chair in Pancreatic Cancer
Harvard Medical School
Dana-Farber Cancer Institute
Boston, MA
Disclosures: Consulting/advisory board: Agenus, BeiGene, EcoR1 Capital, Harbinger Health, Ipsen, Mirati/Bristol Myers Squibb (BMS), Revolution Medicines, Tango Therapeutics, Third Rock Ventures; Funding (paid to institution): Agios, Amgen, AstraZeneca, Eli Lilly, Harbinger Health, Novartis, Revolution Medicines.
Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
This podcast, including the narration, was developed by PER® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on targeted therapy approaches for metastatic PDAC, go to https://www.gotoper.com/annual-oncology-meeting-25-pdac-activity
Release Date

July 30, 2025
Expiration Date

July 30, 2026

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

59 episodes

#Science #Biology #Podcasting Education #Medicine #Spectives